Figure 2 | British Journal of Cancer

Figure 2

From: Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials

Figure 2

Cytoplasmic but not stromal SPARC expression correlates with inferior overall survival ( A, C and E ) and progression-free survival ( B, D and F ) of aPDAC patients. Univariate analysis (Kaplan–Meier curves and log-rank tests) of (A and B) stromal and (C and D) cytoplasmic SPARC expression as a biomarker in the tumour tissue of aPDAC pts treated with palliative, non-nab-paclitaxel containing chemotherapy; cytoplasmic SPARC expression in the (E and F) primary tumour subgroup. Crossed lines indicate censored cases.

Back to article page